Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Purpose
This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
Conditions
- BRAF NP_004324.2:p.V600X
- Metastatic Melanoma
- Progressive Disease
- Recurrent Melanoma
- Stage III Cutaneous Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Cutaneous Melanoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- STEP 1
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1
- Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab
or dabrafenib + trametinib on the developing human fetus are unknown
- All females of childbearing potential must have a blood test or urine study
within 2 weeks prior to registration to rule out pregnancy
- A female of childbearing potential is any woman, regardless of sexual orientation
or whether they have undergone tubal ligation, who meets the following criteria:
1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
at any time in the preceding 24 consecutive months)
- The effects of dabrafenib and trametinib or ipilimumab and nivolumab on the developing
human fetus are unknown; furthermore, dabrafenib has been reported to interfere with
the effect of hormone based oral contraceptives; for this reason and because other
therapeutic agents used in this trial are known to be teratogenic, women of
child-bearing potential and sexually active males must agree to use at least two other
accepted and effective methods of contraception and/or to abstain from sexual
intercourse for the duration of their participation in the study, and for at least 4
weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination
with trametinib; women of child-bearing potential must use at least two other accepted
and effective methods of contraception and/or to abstain from sexual intercourse for
at least 5 months after the last dose of nivolumab and/or ipilimumab and sexually
active males must use at least two other accepted and effective methods of
contraception and/or abstain from sexual intercourse for at least 7 months after the
last dose of nivolumab and/or ipilimumab; should a woman become pregnant or suspect
she is pregnant while she is participating in this study, she should inform her
treating physician immediately
- Patients must have unresectable stage III or stage IV disease
- Patients must have measurable disease; all sites of disease must be evaluated within 4
weeks prior to randomization
- Patients must have histological or cytological confirmation of melanoma that is
metastatic or unresectable and clearly progressive
- NOTE: Any patient with BRAF V600 mutant melanoma (whether cutaneous, acral or
mucosal primary) who meets the eligibility criteria is eligible for participation
in this trial; patients with uveal melanoma are not eligible for this trial
- Patients must have BRAF V600 mutation, identified by a Food and Drug Administration
(FDA)-approved test at a Clinical Laboratory Improvement Act (CLIA)-certified lab; if
test at CLIA-certified lab used a non-FDA approved method, information about the assay
must be provided (FDA approved tests for BRAF V600 mutations in melanoma include:
THxID BRAF Detection Kit and Cobas 4800 BRAF V600 Mutation Test, Foundation Medicine);
prompt information on tumor BRAF mutation status can also be obtained via Novartis
"knowNow" Program
- Patients may have had prior systemic therapy in the adjuvant setting; however this
adjuvant treatment must not have included a CTLA4 or PD1 pathway blocking antibody or
a BRAF/MEK inhibitor; also, patients may not have had any prior systemic treatment for
advanced (measurable metastatic) disease
- Patients must have discontinued chemotherapy, immunotherapy or other investigational
agents used in the adjuvant setting >= 4 weeks prior to entering the study and
recovered from adverse events due to those agents; mitomycin and nitrosoureas must
have been discontinued at least 6 weeks prior to entering the study; patients must
have discontinued radiation therapy >= 1 week prior to entering the study and
recovered from any adverse events associated with treatment; prior surgery must be >=
2 weeks from registration and patients must be fully recovered from post-surgical
complications
- Patients must not receive any other investigational agents while on study or within
four weeks prior to registration
- Patients are ineligible if they have any currently active central nervous system (CNS)
metastases; patients who have treated brain metastases (with either surgical resection
or stereotactic radiosurgery [SRS]) could be eligible; patients must not have taken
any steroids =< 10 days prior to randomization for the purpose of managing their brain
metastases; repeat imaging after SRS or surgical resection is not required so long as
baseline magnetic resonance imaging (MRI) is within 4 weeks of registration; patients
with multiple brain metastases treated with SRS (with [w] or without [w/o] whole-brain
radiotherapy [WBRT]), are not an exclusion; patients with definitive CNS metastases
treated with only WBRT are ineligible; patients with potential CNS metastases that are
too small for treatment with either SRS or surgery (e.g. 1-2 mm) and/or are of
uncertain etiology are potentially eligible, but need to be discussed with and
approved by the study principal investigator (PI)
- Patients must not have other current malignancies, other than basal cell skin cancer,
squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in
situ of the breast; patients with other malignancies are eligible if they have been
continuously disease-free for > 2 years prior to the time of registration
- White blood count >= 3,000/uL (obtained within 4 weeks prior to randomization)
- Absolute neutrophil count (ANC) >= 1,500/uL (obtained within 4 weeks prior to
randomization)
- Platelet count >= 100,000/uL (obtained within 4 weeks prior to randomization)
- Hemoglobin > 8 g/dL (obtained within 4 weeks prior to randomization)
- Serum creatinine =< 1.5 x upper limit of normal (ULN) or serum creatinine clearance
(CrCl) >= 40 ml/min (obtained within 4 weeks prior to randomization)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x
ULN for patients with documented liver metastases)
- Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement
and =< 7 x ULN for patients with known bone involvement) (obtained within 4 weeks
prior to randomization)
- Total bilirubin =< 1.5 x ULN except subjects with normal direct bilirubin or those
with known Gilbert's syndrome (obtained within 4 weeks prior to randomization)
- Patients must not have any serious or unstable pre-existing medical conditions (aside
from malignancy exceptions specified above), including but not limited to, ongoing or
active infection requiring parenteral antibiotics on day 1, or psychiatric
illness/social situations that would limit compliance with study requirements,
interfere with subject's safety, or obtaining informed consent; therapeutic level
dosing of warfarin can be used with close monitoring of prothrombin time
(PT)/international normalized ratio (INR) by the site; exposure may be decreased due
to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted
based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may
be increased and thus close monitoring via PT/INR and warfarin dose adjustments must
be made as clinically appropriate; prophylactic low dose warfarin may be given to
maintain central catheter patency
- Patients must not have a history of or evidence of cardiovascular risks including any
of the following:
- QT interval corrected for heart rate using the Bazett's formula (QTcB) >= 480
msec. at baseline
- History of acute coronary syndromes (including myocardial infarction or unstable
angina), coronary angioplasty, or stenting within the past 24 weeks prior to
registration
- History prior to registration or evidence of current >= class II congestive heart
failure as defined by the New York Heart Association (NYHA) functional
classification system
- Left ventricular ejection fraction (LVEF) =< 45% on cardiac echocardiogram (echo)
or multi gated acquisition scan (MUGA)
- Intra-cardiac defibrillator
- Individuals who are known to be human immunodeficiency virus (HIV) infected are
eligible (note: HIV testing is not required for entry into the study)
- Patients with active autoimmune disease or history of autoimmune disease that might
recur, which may affect vital organ function or require immune suppressive treatment
including systemic corticosteroids, should be excluded; these include but are not
limited to patients with a history of immune related neurologic disease, multiple
sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia
gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE),
connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's,
ulcerative colitis, hepatitis; and patients with a history of toxic epidermal
necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be
excluded because of the risk of recurrence or exacerbation of disease; patients with
vitiligo, endocrine deficiencies including thyroiditis managed with replacement
hormones including physiologic corticosteroids are eligible; patients with rheumatoid
arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with
topical medication and patients with positive serology, such as antinuclear antibodies
(ANA), should be evaluated for the presence of target organ involvement and potential
need for systemic treatment; if no systemic immune suppression is deemed necessary
they can be eligible
- The following medications or non-drug therapies are also prohibited while on treatment
in this study:
- Other anti-cancer therapies
- Other investigational drugs
- Patients taking any medications or substances that are strong inhibitors or
inducers of CYP3A or CYP2C8 are ineligible
- Patients must not have history of retinal vein occlusion (RVO)
- Patients must not have evidence of interstitial lung disease or pneumonitis
- Patients must not have malabsorption, swallowing difficulty, or other conditions that
would interfere with the ingestion or absorption of dabrafenib or trametinib
- STEP 2 (CROSSOVER ARM FOR PATIENTS WITH PROGRESSIVE DISEASE)
- The patient must have met all eligibility criteria (except as detailed below) at the
time of crossover
- RECIST defined measurable disease is not required
- Only prior systemic therapy as part of step 1 is allowed; patients who received
allowed systemic therapy in the adjuvant setting prior to Step 1 and were
eligible for Step 1 are not excluded from proceeding to Step 2 if they meet other
eligibility criteria
- Malabsorption, swallowing difficulty, or other conditions that would interfere
with the ingestion or absorption of dabrafenib or trametinib, or history of
retinal vein occlusion are acceptable for patients crossing over to ipilimumab +
nivolumab treatment
- History of autoimmune disease, excluding interstitial lung disease or
pneumonitis, is allowed in patients crossing over to dabrafenib/trametinib
therapy
- Patients crossing over from nivolumab/ipilimumab to dabrafenib/trametinib who
underwent surgery or SRS to CNS metastases need not be off of steroids to start
treatment
- There is no restriction on serum lactate dehydrogenase (LDH) at crossover
- Patients with a history of cardiovascular risks that developed during step 1 of
therapy should be discussed with study principal investigator (PI) at time of
crossover
- Patients must have melanoma that is metastatic and clearly progressive on prior
therapy
- Patients must be at least 1 week from documented progressive disease (PD) on Step 1 of
current study; all sites of disease must be evaluated within 4 weeks prior to
registration
- Patients must have recovered from adverse events (toxicities resolved to grade 1 or
less) of prior therapy; patients with immune related toxicities from ipilimumab +
nivolumab may continue onto Step 2 even if still on steroids to control side effects,
so long as toxicity has resolved to grade 1 or less
- Patients must have discontinued radiation therapy prior to registering to Step 2 of
the study and recovered from any adverse events associated with treatment; prior
surgery must be >= 2 weeks from registration to Step 2 and patients must be fully
recovered from post-surgical complications
- Patients are ineligible if they have any currently active CNS metastases; patients who
have treated brain metastases (with either surgical resection or stereotactic
radiosurgery [SRS]) could be eligible to proceed; patients crossing over from
dabrafenib/trametinib to nivolumab (nivo)/ipilimumab (ipi) must not have taken any
steroids =< 10 days prior to registration for the purpose of managing their brain
metastases; patients with only whole brain irradiation for treatment of CNS metastases
are ineligible; patients with definitive CNS metastases treated with only WBRT are
ineligible; patients with potential CNS metastases that are too small for treatment
with either SRS or surgery (e.g. 1-2 mm) and/or are of uncertain etiology are
potentially eligible, but need to be discussed with and approved by the study PI
- Patients must not have other current malignancies
- Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab
or dabrafenib + trametinib on the developing human fetus are unknown; all females of
childbearing potential must have a blood test or urine study within 2 weeks prior to
registration to Step 2 crossover to rule out pregnancy; a female of childbearing
potential is any woman, regardless of sexual orientation or whether they have
undergone tubal ligation, who meets the following criteria: 1) has not undergone a
hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal
for at least 24 consecutive months (i.e., has had menses at any time in the preceding
24 consecutive months
- The effects of dabrafenib and trametinib or ipilimumab and nivolumab on the developing
human fetus are unknown; furthermore, dabrafenib has been reported to interfere with
the effect of hormone based oral contraceptives; for this reason and because other
therapeutic agents used in this trial are known to be teratogenic, women of
child-bearing potential and sexually active males must agree to continue to use the
same contraception requirements as on Step 1 of this study (i.e. use at least two
other accepted and effective methods of contraception and/or to abstain from sexual
intercourse for the duration of their participation in the study, and for at least 4
weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination
with trametinib; women of child-bearing potential must use at least two other accepted
and effective methods of contraception and/or to abstain from sexual intercourse for
at least 5
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm A (immunotherapy) |
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C. |
|
|
Experimental Arm B (BRAF inhibitor therapy) |
Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D. |
|
|
Experimental Arm C (BRAF inhibitor therapy) |
Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. |
|
|
Experimental Arm D (immunotherapy) |
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Birmingham, Alabama 35233
Anchorage, Alaska 98508
Anchorage, Alaska 99504
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Fairbanks, Alaska 99701
Kingman, Arizona 86401
Hot Springs, Arkansas 71913
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Anaheim, California 92806
Arroyo Grande, California 93420
Auburn, California 95602
Auburn, California 95603
Baldwin Park, California 91706
Bellflower, California 90706
Berkeley, California 94704
Burbank, California 91505
Burlingame, California 94010
Cameron Park, California 95682
Castro Valley, California 94546
Davis, California 95616
Duarte, California 91010
Fontana, California 92335
Fremont, California 94538
Fresno, California 93720
Harbor City, California 90710
Irvine, California 92618
Los Angeles, California 90027
Los Angeles, California 90034
Los Angeles, California 90095
Site Public Contact
888-798-0719
Modesto, California 95355
Modesto, California 95356
Mountain View, California 94040
Mountain View, California 94040
Novato, California 94945
Oakland, California 94611
Ontario, California 91761
Palo Alto, California 94301
Panorama City, California 91402
Rancho Cucamonga, California 91730
Rancho Mirage, California 92270
Site Public Contact
760-834-3798
Richmond, California 94801
Riverside, California 92505
Roseville, California 95661
Roseville, California 95661
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95825
San Diego, California 92108
San Diego, California 92120
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Marcos, California 92078
San Rafael, California 94903
San Rafael, California 94903
Santa Clara, California 95051
Santa Cruz, California 95065
Santa Rosa, California 95403
Stockton, California 95210
Sunnyvale, California 94086
Vacaville, California 95687
Vallejo, California 94589
Vallejo, California 94589
Walnut Creek, California 94596
Woodland Hills, California 91367
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Denver, Colorado 80210
Denver, Colorado 80218
Durango, Colorado 81301
Durango, Colorado 81301
Englewood, Colorado 80113
Englewood, Colorado 80113
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Grand Junction, Colorado 81505
Greeley, Colorado 80631
Lakewood, Colorado 80228
Littleton, Colorado 80122
Longmont, Colorado 80501
Longmont, Colorado 80501
Loveland, Colorado 80539
Parker, Colorado 80138
Pueblo, Colorado 81004
Hartford, Connecticut 06105
New Haven, Connecticut 06510
New Haven, Connecticut 06520
Norwich, Connecticut 06360
Site Public Contact
860-886-8362
Washington, District of Columbia 20007
Site Public Contact
202-444-2223
Washington, District of Columbia 20010
Site Public Contact
202-877-8839
Aventura, Florida 33180
Daytona Beach, Florida 32114
Site Public Contact
386-254-4211
Miami Beach, Florida 33140
Miami, Florida 33136
Site Public Contact
305-243-2647
Athens, Georgia 30607
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Atlanta, Georgia 30342
Augusta, Georgia 30912
Decatur, Georgia 30033
Savannah, Georgia 31405
Savannah, Georgia 31405
'Aiea, Hawaii 96701
Site Public Contact
808-539-2273
'Aiea, Hawaii 96701
Site Public Contact
808-487-7447
'Aiea, Hawaii 96701
Site Public Contact
808-486-6000
'Aiea, Hawaii 96701
Site Public Contact
808-678-9000
Honolulu, Hawaii 96813
Site Public Contact
808-524-6115
Honolulu, Hawaii 96813
Site Public Contact
808-532-0315
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Site Public Contact
808-545-8548
Honolulu, Hawaii 96813
Site Public Contact
808-522-4333
Honolulu, Hawaii 96813
Site Public Contact
808-586-2979
Honolulu, Hawaii 96817
Site Public Contact
808-536-4888
Honolulu, Hawaii 96817
Site Public Contact
808-531-8521
Honolulu, Hawaii 96817
Site Public Contact
808-547-9816
Honolulu, Hawaii 96817
Site Public Contact
808-547-6881
Honolulu, Hawaii 96819
Honolulu, Hawaii 96826
Site Public Contact
808-983-6090
Lihue, Hawaii 96766
Site Public Contact
808-535-7960
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Emmett, Idaho 83617
Fruitland, Idaho 83619
Meridian, Idaho 83642
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83686
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Twin Falls, Idaho 83301
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Evanston, Illinois 60201
Site Public Contact
847-570-2109
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
847-570-2109
Highland Park, Illinois 60035
Site Public Contact
847-570-2109
Joliet, Illinois 60435
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Macomb, Illinois 61455
Mattoon, Illinois 61938
Ottawa, Illinois 61350
Pekin, Illinois 61554
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Site Public Contact
217-788-3528
Swansea, Illinois 62226
Swansea, Illinois 62226
Urbana, Illinois 61801
Urbana, Illinois 61801
Warrenville, Illinois 60555
Yorkville, Illinois 60560
Evansville, Indiana 47713
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Indianapolis, Indiana 46237
Site Public Contact
317-528-7060
Indianapolis, Indiana 46290
Michigan City, Indiana 46360
Mooresville, Indiana 46158
Site Public Contact
317-834-3603
Newburgh, Indiana 47630
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Site Public Contact
515-956-4132
Boone, Iowa 50036
Site Public Contact
515-956-4132
Clive, Iowa 50325
Clive, Iowa 50325
Council Bluffs, Iowa 51503
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Sioux City, Iowa 51101
West Des Moines, Iowa 50266
Chanute, Kansas 66720
Coffeyville, Kansas 67337
Site Public Contact
620-252-1606
Dodge City, Kansas 67801
El Dorado, Kansas 67042
Garden City, Kansas 67846
Great Bend, Kansas 67530
Hays, Kansas 67601
Site Public Contact
785-623-5774
Independence, Kansas 67301
Kansas City, Kansas 66112
Kansas City, Kansas 66160
Kingman, Kansas 67068
Lawrence, Kansas 66044
Liberal, Kansas 67905
Manhattan, Kansas 66502
McPherson, Kansas 67460
Newton, Kansas 67114
Olathe, Kansas 66061
Overland Park, Kansas 66209
Overland Park, Kansas 66210
Parsons, Kansas 67357
Pittsburg, Kansas 66762
Site Public Contact
620-235-7900
Pratt, Kansas 67124
Salina, Kansas 67401
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Wellington, Kansas 67152
Westwood, Kansas 66205
Wichita, Kansas 67208
Wichita, Kansas 67208
Wichita, Kansas 67214
Wichita, Kansas 67214
Winfield, Kansas 67156
Bardstown, Kentucky 40004
Corbin, Kentucky 40701
Lexington, Kentucky 40504
Lexington, Kentucky 40509
Louisville, Kentucky 40202
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Louisville, Kentucky 40215
Louisville, Kentucky 40245
Shepherdsville, Kentucky 40165
Baton Rouge, Louisiana 70805
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70816
Baton Rouge, Louisiana 70836
Covington, Louisiana 70433
Houma, Louisiana 70360
Kenner, Louisiana 70065
New Orleans, Louisiana 70112
New Orleans, Louisiana 70112
New Orleans, Louisiana 70121
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Baltimore, Maryland 21229
Site Public Contact
410-368-2910
Baltimore, Maryland 21237
Site Public Contact
443-777-7364
Frederick, Maryland 21701
Frederick, Maryland 21702
Site Public Contact
301-668-7043
Springfield, Massachusetts 01104
Site Public Contact
413-748-9234
Springfield, Massachusetts 01199
Adrian, Michigan 49221
Site Public Contact
517-265-0116
Ann Arbor, Michigan 48106
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Canton, Michigan 48188
Canton, Michigan 48188
Caro, Michigan 48723
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Detroit, Michigan 48201
Detroit, Michigan 48236
East China Township, Michigan 48054
Escanaba, Michigan 49829
Farmington Hills, Michigan 48334
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49048
Lansing, Michigan 48912
Livonia, Michigan 48154
Livonia, Michigan 48154
Macomb, Michigan 48044
Macomb, Michigan 48044
Marlette, Michigan 48453
Monroe, Michigan 48162
Site Public Contact
800-444-3561
Muskegon, Michigan 49444
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Port Huron, Michigan 48060
Port Huron, Michigan 48060
Reed City, Michigan 49677
Rochester Hills, Michigan 48309
Saginaw, Michigan 48601
Saginaw, Michigan 48604
Sterling Heights, Michigan 48312
Tawas City, Michigan 48764
Warren, Michigan 48088
Warren, Michigan 48093
Warren, Michigan 48093
Warren, Michigan 48093
Warren, Michigan 48093
West Branch, Michigan 48661
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Detroit Lakes, Minnesota 56501
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Edina, Minnesota 55435
Fergus Falls, Minnesota 56537
Fosston, Minnesota 56542
Fridley, Minnesota 55432
Hibbing, Minnesota 55746
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55454
Park Rapids, Minnesota 56470
Robbinsdale, Minnesota 55422
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Stillwater, Minnesota 55082
Thief River Falls, Minnesota 56701
Site Public Contact
605-312-3320
Virginia, Minnesota 55792
Woodbury, Minnesota 55125
Worthington, Minnesota 56187
Site Public Contact
605-312-3320
Pascagoula, Mississippi 39581
Site Public Contact
228-809-5292
Bonne Terre, Missouri 63628
Site Public Contact
314-996-5569
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Jefferson City, Missouri 65109
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64131
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Bozeman, Montana 59715
Butte, Montana 59701
Site Public Contact
406-723-2621
Great Falls, Montana 59405
Helena, Montana 59601
Kalispell, Montana 59901
Missoula, Montana 59802
Bellevue, Nebraska 68123
Grand Island, Nebraska 68803
Kearney, Nebraska 68847
Lincoln, Nebraska 68506
Site Public Contact
402-484-4911
Lincoln, Nebraska 68510
Lincoln, Nebraska 68510
Site Public Contact
402-327-7363
Norfolk, Nebraska 68701
North Platte, Nebraska 69101
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68122
Omaha, Nebraska 68124
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68130
Site Public Contact
402-334-4773
Omaha, Nebraska 68131
Papillion, Nebraska 68046
Scottsbluff, Nebraska 69361
Carson City, Nevada 89703
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89074
Henderson, Nevada 89074
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Las Vegas, Nevada 89103
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
Las Vegas, Nevada 89109
Las Vegas, Nevada 89109
Las Vegas, Nevada 89109
Las Vegas, Nevada 89113
Las Vegas, Nevada 89119
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89135
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89148-2405
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89149
Las Vegas, Nevada 89169
Las Vegas, Nevada 89169
Pahrump, Nevada 89048
Reno, Nevada 89502
Reno, Nevada 89503
Reno, Nevada 89509
Hackensack, New Jersey 07601
Site Public Contact
201-996-2879
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87109
Las Cruces, New Mexico 88011
Rio Rancho, New Mexico 87124
Cooperstown, New York 13326
Clinton, North Carolina 28328
Goldsboro, North Carolina 27534
Goldsboro, North Carolina 27534
Hendersonville, North Carolina 28791
Jacksonville, North Carolina 28546
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58103
Site Public Contact
701-234-6161
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Preston D. Steen
712-252-0088
Fargo, North Dakota 58122
Jamestown, North Dakota 58401
Centerville, Ohio 45459
Centerville, Ohio 45459
Cincinnati, Ohio 45220
Cincinnati, Ohio 45242
Cincinnati, Ohio 45247
Cincinnati, Ohio 45255
Cleveland, Ohio 44109
Cleveland, Ohio 44111
Cleveland, Ohio 44195
Columbus, Ohio 43210
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Dayton, Ohio 45406
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Franklin, Ohio 45005
Greenville, Ohio 45331
Kettering, Ohio 45409
Kettering, Ohio 45429
Mansfield, Ohio 44906
Mayfield Heights, Ohio 44124
Newark, Ohio 43055
Newark, Ohio 43055
Perrysburg, Ohio 43551
Portsmouth, Ohio 45662
Sandusky, Ohio 44870
Toledo, Ohio 43623
Site Public Contact
419-407-1160
Toledo, Ohio 43623
Site Public Contact
800-444-3561
Troy, Ohio 45373
Troy, Ohio 45373
Warrensville Heights, Ohio 44122
Wooster, Ohio 44691
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73109
Baker City, Oregon 97814
Bend, Oregon 97701
Clackamas, Oregon 97015
Clackamas, Oregon 97015
Coos Bay, Oregon 97420
Newberg, Oregon 97132
Ontario, Oregon 97914
Portland, Oregon 97213
Portland, Oregon 97225
Redmond, Oregon 97756
Site Public Contact
541-706-2909
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
Danville, Pennsylvania 17822
East Stroudsburg, Pennsylvania 18301
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Ephrata, Pennsylvania 17522
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Hanover, Pennsylvania 17331
Site Public Contact
877-441-7957
Hazleton, Pennsylvania 18201
Hazleton, Pennsylvania 18201
Site Public Contact
570-501-1242
Lebanon, Pennsylvania 17042
Lewisburg, Pennsylvania 17837
Lewistown, Pennsylvania 17044
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15224
Site Public Contact
412-578-5000
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pottsville, Pennsylvania 17901
Sayre, Pennsylvania 18840
Site Public Contact
800-836-0388
Scranton, Pennsylvania 18510
Selinsgrove, Pennsylvania 17870
State College, Pennsylvania 16801
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wexford, Pennsylvania 15090
Wilkes-Barre, Pennsylvania 18711
York, Pennsylvania 17403
Site Public Contact
877-441-7957
York, Pennsylvania 17403
Site Public Contact
877-441-7957
Easley, South Carolina 29640
Greenville, South Carolina 29601
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29607
Greenville, South Carolina 29615
Greer, South Carolina 29650
Hilton Head Island, South Carolina 29926
Seneca, South Carolina 29672
Spartanburg, South Carolina 29307
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57105
Sioux Falls, South Dakota 57117-5134
Chattanooga, Tennessee 37403
Site Public Contact
423-778-6947
Franklin, Tennessee 37067
Site Public Contact
800-811-8480
Kingsport, Tennessee 37660
Kingsport, Tennessee 37660
Nashville, Tennessee 37204
Site Public Contact
800-811-8480
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Bryan, Texas 77802
Charlottesville, Virginia 22908
Norton, Virginia 24273
Aberdeen, Washington 98520
Auburn, Washington 98001
Bainbridge Island, Washington 98110
Bellevue, Washington 98004
Bellingham, Washington 98225
Bremerton, Washington 98310
Bremerton, Washington 98310
Burien, Washington 98166
Centralia, Washington 98531
Edmonds, Washington 98026
Enumclaw, Washington 98022
Everett, Washington 98201
Federal Way, Washington 98002
Federal Way, Washington 98003
Gig Harbor, Washington 98332
Gig Harbor, Washington 98335
Issaquah, Washington 98029
Kennewick, Washington 99336
Kennewick, Washington 99336
Lacey, Washington 98503
Lakewood, Washington 98499
Longview, Washington 98632
Lynnwood, Washington 98036
Port Townsend, Washington 98368
Site Public Contact
360-344-3091
Poulsbo, Washington 98370
Puyallup, Washington 98372
Puyallup, Washington 98372
Renton, Washington 98055
Seattle, Washington 98101
Seattle, Washington 98104
Seattle, Washington 98107
Seattle, Washington 98122-4307
Seattle, Washington 98122-5711
Sedro-Woolley, Washington 98284
Site Public Contact
360-788-8240
Shelton, Washington 98584
Spokane Valley, Washington 99216
Spokane, Washington 99204
Spokane, Washington 99218
Tacoma, Washington 97405
Tacoma, Washington 98405
Tacoma, Washington 98405
Tacoma, Washington 98405
Vancouver, Washington 98664
Walla Walla, Washington 99362
Yakima, Washington 98902
Yelm, Washington 98597
Bridgeport, West Virginia 26330
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Huntington, West Virginia 25701
Site Public Contact
304-399-6617
Martinsburg, West Virginia 25401
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Antigo, Wisconsin 54409
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Chippewa Falls, Wisconsin 54729
Eau Claire, Wisconsin 54701
Green Bay, Wisconsin 54301-3526
Brian L. Burnette
920-433-8889
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Brian L. Burnette
920-433-8889
Green Bay, Wisconsin 54303
Johnson Creek, Wisconsin 53038
Ladysmith, Wisconsin 54848
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Manitowoc, Wisconsin 54221
Site Public Contact
920-320-2749
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-4380
Minocqua, Wisconsin 54548
Oconto Falls, Wisconsin 54154
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Sturgeon Bay, Wisconsin 54235-1495
Sturgeon Bay, Wisconsin 54235
Brian L. Burnette
920-433-8889
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wausau, Wisconsin 54401
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
Wisconsin Rapids, Wisconsin 54494
More Details
- NCT ID
- NCT02224781
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVES:
I. To determine whether initial treatment with either combination ipilimumab + nivolumab (with subsequent dabrafenib mesylate [dabrafenib] in combination with trametinib dimethyl sulfoxide [trametinib]) or dabrafenib in combination with trametinib (with subsequent ipilimumab + nivolumab) significantly improves 2 year overall survival (OS) in patients with unresectable stage III or stage IV BRAFV600 mutant melanoma.
SECONDARY CLINICAL OBJECTIVES:
I. To evaluate the impact of initial treatment on median OS and hazard ratio for death.
II. To determine whether initial treatment choice significantly improves 3 year OS.
III. To evaluate the anti-tumor activities (Response Evaluation Criteria in Solid Tumors [RECIST]-defined response rate, median progression-free survival [PFS]) and safety profiles of ipilimumab + nivolumab and dabrafenib-trametinib in a Cooperative Group trial of patients with V600 mutant melanoma.
IV. To evaluate the activity (RECIST-defined response rate, median PFS) and safety of dabrafenib + trametinib in patients who have had disease progression on ipilimumab + nivolumab and in comparison to its activity and safety in ipilimumab + nivolumab naive patients.
V. To evaluate the activity of ipilimumab + nivolumab (RECIST-defined response rate, median PFS) and safety in patients who have had disease progression on dabrafenib + trametinib and in comparison to its activity and safety in dabrafenib + trametinib naive patients.
VI. To assess the feasibility of crossover to the alternative treatment strategy (percentage of patients who are able to crossover from one arm to the other and complete at least an initial course [12 weeks] of treatment after cross-over without intervening symptomatic disease progression or treatment limiting toxicity).
SECONDARY LABORATORY OBJECTIVES:
I. Association of inherited variation with immune mediated adverse events and response to ipilimumab + nivolumab.
Ia. To determine the association of inherited genetic variation and immune-associated adverse events in patients with metastatic melanoma treated with ipilimumab containing regimens by completing candidate-based gene and pathway analyses of genes involved in lymphocyte activation, cytokines, cytokine receptors and within the major histocompatibility complex (MHC) region and an agnostic genome-wide single nucleotide polymorphism (SNP)-based approach.
Ib. To investigate the association between inherited genetics and survival in patients with metastatic melanoma treated with ipilimumab containing regimens by completing candidate-based gene and pathway analyses of genes involved in lymphocyte activation, cytokines profile, cytokine receptors and within the MHC region and an agnostic genome-wide SNP-based approach.
Ic. To replicate genomic markers identified in the above aims in an independent sample set of patients treated with ipilimumab containing regimens and preliminarily characterize their potential functional role by completing replication of variation as associated with immune-related adverse events (irAEs) and survival and bio-informatic assessment of genomic markers.
II. To determine the utility of circulating BRAF levels in determining the response and resistance to either BRAF/MEK directed and/or combination immunotherapy in patients with BRAF mutant melanoma.
IIa. To determine if changes in blood BRAF levels utilizing peripheral blood BRAFV600 mutational testing in patients with stage IV BRAF mutant melanoma correlate with response and resistance to combination BRAF/MEK directed therapy.
IIb. To determine if changes in blood BRAF levels utilizing peripheral blood BRAFV600 mutational testing in patients with stage IV BRAF mutant melanoma correlate with response and resistance to combination immunotherapy.
IIc. To compare the kinetics of peripheral blood BRAFV600 levels during response and resistance in groups of patients receiving BRAF targeted therapy or combination immunotherapy as initial therapy.
IId. To compare the kinetics of peripheral blood BRAFV600 levels during response and resistance to combination BRAF targeted therapy or combination immunotherapy in individual patients (initial treatment vs crossover treatment).
SECONDARY PATIENT REPORTED OUTCOMES OBJECTIVES:
I. To evaluate differences in overall health between initial treatment arms (dabrafenib + trametinib vs. ipilimumab + nivolumab immunotherapy) at 2 years, accounting for toxicities and overall survival. (Primary) II. To assess differences in overall function over 2 years between initial treatment with dabrafenib + trametinib vs. ipilimumab + nivolumab. (Secondary) III. To document the effects of treatment crossover and treatment administration sequence on symptom burden and overall function. (Secondary) IIIa. To compare differences in function and symptoms by treatment sequence for ipilimumab + nivolumab (arm A vs. D), and dabrafenib + trametinib, (arm B vs. C) at baseline, 6 weeks, 12 weeks, and 6 months after the initiation of each treatment.
IIIb. To describe the frequency and severity of treatment toxicities at baseline, 6 weeks, 12 weeks, and 6 months after initiation of each treatment.
EXPLORATORY TOBACCO USE OBJECTIVES:
I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events [both clinical and hematologic] and dose modifications).
II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms.
III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization.
IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit.
OUTLINE: Patients are randomized to 1 of 2 treatment arms (Arm A or Arm B).
ARM A:
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab intravenously (IV) over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C.
ARM C: Patients receive dabrafenib mesylate orally (PO) twice daily (BID) and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D.
ARM D:
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.